Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shannon Chadha

Allergy & Immunology Charlotte, NC Medical Doctor

NPI 1073774964 CMS profile 906164

2600 E 7Th St, Unit A, Charlotte, NC 28204

Open in the dashboard

General payments

$21,917

908 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Chadha of Charlotte, NC is reported in the CMS Open Payments database as having received $21,917 across 908 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,158 151
2024 General $3,156 126
2023 General $4,000 143
2022 General $3,494 139
2021 General $2,543 123
2020 General $1,974 106
2019 General $2,591 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Chadha
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Shannon Chadha were reported at $4,158. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Shannon Chadha Allergy & Immunology median Middle half National median
2019 $2,591 $594 $163–$1,512 $163
2020 $1,974 $426 $106–$1,233 $114
2021 $2,543 $638 $157–$1,708 $132
2022 $3,494 $790 $205–$1,961 $149
2023 $4,000 $852 $220–$2,147 $160
2024 $3,156 $865 $203–$2,267 $164
2025 $4,158 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,971 151 payments
  2. Regeneron Healthcare Solutions, Inc. $3,422 95 payments
  3. GlaxoSmithKline, LLC. $2,310 124 payments
  4. CSL Behring $1,459 59 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $1,324 56 payments
  6. Genzyme Corporation $1,195 43 payments
  7. Pfizer Inc. $924 57 payments
  8. Grifols USA, LLC $860 51 payments
  9. Amgen Inc. $725 30 payments
  10. BioCryst US Sales Co., LLC $591 26 payments
  11. Other $5,137 216 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,533 895 payments
  2. Education $210 4 payments
  3. Consulting Fee $174 9 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $2,651 77 payments
  2. FASENRA $1,301 57 payments
  3. NUCALA $1,201 64 payments
  4. DUPIXENT Immunology $1,137 37 payments
  5. TEZSPIRE Respiratory $1,046 27 payments
  6. DUPIXENT Immunology And Inflammation $919 19 payments
  7. Haegarda $766 35 payments
  8. TEZSPIRE Inflammation $713 29 payments
  9. Xembify $663 38 payments
  10. Hizentra $618 21 payments
  11. Other $12,264 577 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

981

Median for Allergy/ Immunology: 449

Drug cost

$605,996

Median for Allergy/ Immunology: $169,700

Branded share of claims

28.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 27 $316,634
Xembify Immune Globulin,gamma(Igg)klhw Brand 16 $100,761
Dupixent Syringe Dupilumab Brand 13 $87,886
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $17,340
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $12,498
Breo Ellipta Fluticasone/Vilanterol Brand 20 $12,375
Advair Hfa Fluticasone Propion/Salmeterol Brand 22 $11,331
Symbicort Budesonide/Formoterol Fumarate Brand 21 $9,199
Azelastine Hcl Generic 199 $6,146
Cyclosporine Modified Cyclosporine, Modified Brand 19 $5,774

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$201,019

Of which drugs: $142,510

Medicare patients

193

Average age 72

Services billed

12,197

148 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 44%
Depression 26%
Diabetes 25%
Osteoporosis 24%
Ischemic heart disease 22%
Chronic kidney disease 18%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $547
  • Regeneron Pharmaceuticals, Inc. $105
  • GENZYME CORPORATION $77
$729 13 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $244
  • Amgen Inc. $137
$381 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $266
$266 — —
Hizentra
  • CSL Behring $261
$261 27 —
CUTAQUIG
  • Octapharma USA, Inc. $151
  • PFIZER INC. $23
$174 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

908 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record